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ABSTRACT
The goal of the Norwegian Ministry of Health and Care Services is to offer an equal health-care
service with the same outcomes wherever people are living within the country. The aim of this
study was to evaluate whether this was true for patients diagnosed with metastatic prostate
cancer (mPC) and living in Nordland County, a region with a challenging geography and climate
and having, several small and remote communities and only 1 department of oncology. The latter
is located in the main city, Bodø. We also compared a subgroup living in communities having
lower average annual income (less than NOK 240,000 (equivalent to USD 28,600)) with patients
living in Bodø (NOK 285,000 (USD 33,900)). Overall 288 patients were included and stratified into
3 subgroups (favourable distance and income, unfavourable distance and income, and unfavour-
able distance and favourable income). No statistically significant differences were observed
regarding patient characteristics. There was no indication towards under-treatment among
patients from the distant regions or the lower income region. Given that disparities were not
observed, it was not surprising to see comparable survival outcomes (p=0.35). In conclusion,
these results suggest that the health-care system in Nordland County successfully delivers state-
of-the-art oncology care to patients with mPC.
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Introduction
Equal access to affordable health care is not guaran-
teed for all cancer patients in Europe, North America
and the circumpolar region, where a variety of differ-
ent health-care systems exist and where several stu-
dies have described disparities that explain variations
in survival outcomes not only between countries but
also within some countries’ populations [1–7]. For
example, rural patients and those from low average
annual income regions have been reported experien-
cing reduced access to high-quality oncology care [8–
10]. The publicly funded Norwegian health-care sys-
tem aims to avoid disparities [11,12] and financial
barriers to oncology care, e.g., by providing travel
and accommodation. The goal of the Norwegian
Ministry of Health and Care Services (HOD) is to pro-
vide good and equal health and care services to the
population of Norway. Even within the rural, arctic
region of North Norway, with several small islands,
long fjords and remote small communities, not all
patients have large travel distances to the main and
local hospitals [13]. Norway has been known for a
policy aiming to minimize poverty and offer public
health insurance to all inhabitants. Consequently, dif-
ferences in average income between various sub-
groups of the population have been restricted.
However, the average annual income varies by com-
munity and has been reported to be less than NOK
240,000 (USD 28,600) in several small communities in
our county (Nordland) [14]. In contrast, the average
annual income among inhabitants of Bodø (the capi-
tal of Nordland County, approximately 50,000 inhabi-
tants) was NOK 285,000 (19% higher). The region’s
main hospital, and the only 1 with a department of
oncology, is also located in Bodø. Many patients have
to travel more than 200 km (often by air or by sea) to
personally consult with an oncologist or receive radio-
therapy. Systemic treatment is also administered at
local hospitals, which consult with an oncologist via
weekly virtual, web-based meetings. There are a total
of 6 local hospitals in Nordland County and 5 of them
are connected to the Nordland hospital trust. Due to
these circumstances, regular monitoring of pattern of
care and outcome is necessary to ensure the health-
care system is well aligned to its political and social
CONTACT Carsten Nieder carsten.nieder@nlsh.no Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø 8092, Norway
INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH
2019, VOL. 78, 1620086
https://doi.org/10.1080/22423982.2019.1620086
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
framework. Therefore, we studied the pattern of care
and survival among a sample consisting of men with
metastatic prostate cancer (mPC), stratified by home
community within the county of Nordland.
Material and methods
This retrospective study included 288 consecutive men
(all Caucasian) with mPC who received oncology care at
the Nordland hospital Bodø (academic teaching hospital
in rural North Norway). Some patients presented with
metastases at diagnosis, others later during the disease
trajectory. In all cases, metastatic disease was diagnosed
some time between 2003 and 2015. National clinical
pathways ensure that diagnostic procedures, after a sus-
pected cancer diagnosis, eventually lead to initiation of
treatment within specified time frames. Systemic treat-
ment was given according to the National guidelines. It
did not include early docetaxel during the hormone-
sensitive stage in this study. Palliative radiotherapy was
utilized for different indications, e.g. painful bone metas-
tases or metastatic spinal cord compression. We arbitra-
rily defined a potentially favourable subgroup of patients,
which included those who lived in the higher income
area close to the Nordland hospital Bodø. An unfavour-
able subgroup included patients who had larger travel
distance and lived in communities with lower average
annual income. All remaining patients formed the inter-
mediate group. The regional electronic patient record
(EPR) system, named DIPS®, was used to collect all fol-
low-up, treatment and baseline data. Patient relocation
was also identified in the EPR and led to exclusion from
further analysis. Actuarial survival from the diagnosis of
metastatic disease and from first cancer diagnosis was
calculated with the Kaplan–Meier method and compared
between subgroups with differing baseline characteris-
tics with the log-rank test. Fourteen patients were cen-
sored at the time of last follow-up (22–64 months,
median 36 months). Associations between different vari-
ables of interest were assessed with the chi-square or
Fisher exact probability test (2-tailed). A p-value ≤0.05
was considered statistically significant. Based on the
number of patients who lived in Bodø (n = 76), we
estimated that we were able to detect a difference in 2-
year survival of 22% if the other group of patients had




While 76 patients (26%) lived in Bodø, i.e. closest to
the department of oncology (favourable distance
and income area), 28 (10%) lived in 7 distant small
communities with average annual income below
NOK 240,000 (unfavourable distance and income
area). These communities included Nesna, Leirfjord,
Hemnes, Hamarøy, Tysfjord, Øksnes and Bø (1,800–
4,500 inhabitants). The remaining 184 patients (64%)
lived at variable distances from Bodø (<100 km and
also >200 km) in small- or medium-sized commu-
nities (smallest: Røst (500 inhabitants), largest: Rana
(26,000)). These communities had higher average
annual incomes than NOK 240,000 but did not
exceed the Bodø income. Further patient character-
istics are shown in Table 1. None of the differences
was statistically significant. However, the patients
from the unfavourable distance and income area
tended to be younger and healthier.

















Group size 76 28 184
Synchronous met. 25 33 13 46 58 32
Metachronous met. 51 67 15 54 126 68
Gleason score 8–10 36 47 16 57 105 57
Gleason score <8 40 53 12 43 79 43
Less than 5 bone met. 48 63 19 67 121 66
More than 5 bone met. 28 37 9 32 63 34
Visceral met. 17 22 5 18 43 23
Bone met. only 59 78 23 82 141 77
CCI 0 34 45 18 64 85 46
CCI ≥1 42 55 10 36 99 54
Not married/partnered 19 25 6 21 42 23
PSA (median, range) 57 4–10,300 194 3–3,700 74 3–4,871
Age (median, range) 76 56–90 71.5 56–86 75 56–94
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Treatment details
Systemic treatment for castration-resistant disease
included docetaxel, cabazitaxel, enzalutamide and abirater-
one acetate. Some patients received bone-targeting agents
(often zoledronic acid or denosumab) alone or in combina-
tion with other systemic treatment. The proportion of
patients without any such treatment was highest in Bodø
(46%, p = 0.075, Table 2). Almost all patients who received
no systemic treatment did so as a result of physician choice
(poor performance status, frailty, comorbidities). After
exclusion of patients who received bone-targeting drugs
alone, the proportion of untreated patients remained
higher in Bodø (66%, p = 0.16). The proportion of patients
who received at least 2 sequential lines, e.g. docetaxel plus
cabazitaxel or enzalutamide plus docetaxel, was lowest in
Bodø (14%, p = 0.048). Comparable to the utilization of
systemic treatment, there was no indication towards
under-treatment with palliative bone radiotherapy in the
distant/lower income region. Actually, the rate of 80% was
highest among all 3 regions.
Overall survival
Median survival from diagnosis of distant metastases is
shown in Figure 1. It was shortest in the subgroup from
Bodø (19.2 months as compared to 23.1 and 24.7
months, p = 0.35). And 41%,, 46%, and 51% of the
patients were alive after 2 years. Also, median survival
from initial diagnosis of prostate cancer was shortest in
the Bodø group (60.5 vs 70.3 and 68.2 months, p = 0.68,
Kaplan–Meier curves not shown).
An additional analyses of 2 subgroups were per-
formed. The first one included all patients who lived
in communities with average annual income < NOK
240,000 and the second one those who lived in com-
munities with income ≥ NOK 240,000 (range 240,000–
285,000). The median income for these 2 subgroups
was NOK 250,000 and 230,000, respectively. Median
survival from diagnosis of distant metastases was 23.6
(higher income) and 22.2 months (lower income),
respectively (p = 0.86).
Discussion
We performed a comprehensive analysis of pattern of
treatment and survival in men with metastatic prostate
cancer. The study cohort consisted mainly of elderly,
retired men (median age >70 years, most of them
married or partnered) with bone-only metastases.
Typically, metastatic disease developed after an initial
period of locally or locoregionally confined cancer. Most
patients (76%) did not live close to the county’s only
department of oncology, located in Bodø. We decided
to stratify for travel distance (Bodø vs. other commu-
nities) and, since previous research from other parts of
the world identified lower average annual income as a
source of disparities that may cause shorter survival
[3,7,15], we also analysed a subgroup with both longer
travel distance and lower community income. The latter
patients lived in 7 different small communities (<5,000
inhabitants), each without a local hospital. As a

















Group size 74 25 181
No systemic treatment* 34 46 9 36 56 31
Systemic treatment 40 54 16 64 125 69
Chemo, Enza or AA 25 34 12 48 84 46
Second-line chemo, Enza or AAa 10 14 7 28 50 28
Bone radiotherapy 53 72 20 80 123 68
Ra-223 4 5 1 4 10 6
Figure 1. Actuarial Kaplan–Meier survival curves for patients
from 3 different geographic areas (Bodø: favourable distance
and income (coded “0”); 7 small communities: unfavourable
distance and income (coded “1”); other communities: unfavour-
able distance, favourable income (coded “2”)). The median was
19.2, 23.1 and 24.7 months, respectively (p = 0.35).
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limitation of this methodology, it should be noted that
information about the patients’ actual income and per-
sonal economy was not available. In addition, the dif-
ference of 19% in average annual income between the
lower income communities and the city of Bodø was
modest.
Our publicly funded health-care system provides free
travel and accommodation to patients referred to spe-
cialist care (except for a minor share covered by the
patients). Primary care is provided by each individual
community (physicians responsible for general care
and, if needed, referral to specialist care; home care
provided by nurses and oncology nurses; nursing
homes; rehabilitation; cancer care coordinator). In con-
trast to larger cities, small communities often experi-
ence difficulties in recruiting staff, resulting for example
in unstable access to primary care physicians. Moreover,
many of these communities are unable to offer a cancer
coordinator and/or oncology nurses. Unlike other sys-
tems, individual insurance status does not cause any
bias (faster access, more advanced treatment, etc.), as
private health-care insurance is rare.
Further limitations of this study include the number
of patients, statistical power of subgroup analyses, and
retrospective design. In a larger cohort of patients, the
different baseline characteristics, e.g., age, might have
reached the level of statistical significance. Information
about time to diagnosis was not available in our data-
base. Thus, we cannot exclude the possibility that delay
caused by the primary care sector may have influenced
outcomes, and that such delay may vary between the
subgroups examined. Regarding time to oncology clinic
assessment, we have always ensured equal access with
typical waiting times of 1–2 weeks and emergency
access when needed. A strength of our study is the
completeness of data, ensured by the fact that the
electronic patient record also includes information
from all local hospitals in the county. The absence of
other oncology care providers further enhances the
data quality.
We wanted to confirm that all patients in our region
have equal access to systemic therapy and radiotherapy,
and that our health-care system achieves comparable
survival outcomes irrespective of distance to the depart-
ment of oncology. Access to smaller and less specialized
local hospitals, which can provide systemic treatment and
participate in video-streamed multidisciplinary tumour
boards and virtual meetings with oncologists, provides a
framework for quality care also in the most remote areas
of our sparsely populated county. In general, adherence
to national guidelines is high in North Norway and the
outcomes for patients with mPC are comparable to those
reported from other parts of the world [16]. Patients
without medical contraindications are eligible for sequen-
tial treatment with docetaxel, cabazitaxel, enzalutamide
and abiraterone acetate, i.e. all drugs endorsed by the
committee that decides on availability of systemic treat-
ments in Norway. Ra-223 was available, too. These drugs
are identical to those utilized in other high-income coun-
tries [17,18]. The present results confirm the efficacy of the
regional structures and treatment pathways, because the
reference patients who lived in the surrounding of the
main hospital in Bodø, where the average annual income
is relatively high, did not receive significantly more
intense treatment. Survival was actually numerically bet-
ter in the other regions (no statistical significance), mean-
ing that there is no reason to be concerned about
clinically meaningful disparities. The fact that survival
was better in the other regions is plausible, because
more patients had received systemic treatment, a prere-
quisite for prolongation of survival. Moreover, utilization
of more than one line of systemic treatment also was
more common and favoured patients from other regions.
The reason for differences in nature and intensity of treat-
ment is eligibility (and safety), i.e. the oncologist’s assess-
ment of performance status, symptom burden, organ
function, comorbidity and contraindications. Imbalances
in some of these baseline parameters likely existed in the
present retrospective study.
Even if our study was performed in North Norway, the
findings cannot be translated to all other circumpolar
regions, due to socio-economic and population differ-
ences (different indigenous groups and overall popula-
tion heterogeneity, variable prostate cancer incidence),
variable travel distance and infrastructure, and different
health-care systems. In general, lung and colorectal can-
cer were identified as important public health concern
[10]. In Greenland, colorectal cancer stage distribution,
provision of oncological treatment and 5-year survival
were comparable to patients diagnosed and treated in
Denmark [19]. In contrast and based on an earlier pub-
lication, Yukon cancer mortality rates were elevated com-
pared with national, provincial, urban, and southern-rural
jurisdictions [20]. In an ideal world, the transfer of our
current oncology care model to less well-served regions
outside of Norwaymay be considered, yet the economical
consequences and difficulties in recruiting qualified staff
must not be underestimated.
Conclusions
The present results suggest that the health-care system
of the Nordland County successfully delivers state-of-
the-art oncology care to patients with metastatic pros-
tate cancer who live in a rural region with challenging
climate and geography.
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